A 35-year-old multiparous woman (2 living children) presents to the gynaecology clinic 6 weeks after insertion of a copper T 380A IUCD for contraception. She reports heavy menstrual bleeding and severe dysmenorrhea since insertion, requiring frequent changes of pads and occasional absence from work. She denies fever, abnormal discharge, or pelvic pain between menses. Pelvic examination shows a normally positioned uterus with no adnexal masses or tenderness. Transvaginal ultrasound confirms correct IUCD placement in the uterine cavity. What is the most appropriate management?

Explanation

## Clinical Context This patient has: - Heavy menstrual bleeding (menorrhagia) and severe dysmenorrhea post-IUCD insertion - Correct IUCD placement on imaging - No signs of infection, perforation, or expulsion - Symptoms within the expected early adaptation period (6 weeks) ## Why Medical Management with NSAIDs is First-Line **Key Point:** Menorrhagia and dysmenorrhea are common side effects of copper IUCDs, occurring in 10–30% of users. Most women adapt within 3–6 months; only 5–10% require removal due to intolerable bleeding. **High-Yield:** NSAIDs (especially mefenamic acid, a prostaglandin inhibitor) reduce menstrual blood loss by 20–50% in copper IUCD users and are the first-line pharmacological intervention. Mefenamic acid is preferred because it inhibits both prostaglandin synthesis and action. **Clinical Pearl:** The copper IUCD increases endometrial prostaglandin production, which drives increased uterine contractions, vasodilatation, and bleeding. NSAIDs counteract this mechanism. ## Management Algorithm for Copper IUCD-Related Menorrhagia ```mermaid flowchart TD A["Copper IUCD inserted<br/>Menorrhagia ± dysmenorrhea"]:::outcome A --> B{"Time since insertion?"}:::decision B -->|"< 3 months<br/>(adaptation period)"| C["IUCD correctly placed?"]:::decision B -->|"≥ 3 months<br/>persistent symptoms"| D["Consider removal &<br/>alternative method"]:::action C -->|"Yes"| E["Start NSAIDs<br/>during menses"]:::action C -->|"No"| F["Remove IUCD<br/>Manage perforation/expulsion"]:::urgent E --> G{"Response at 3 months?"}:::decision G -->|"Improved/acceptable"| H["Continue IUCD<br/>Ongoing NSAID use"]:::outcome G -->|"Intolerable"| I["Remove IUCD<br/>Offer LNG-IUS or alternative"]:::action D --> I ``` **Key Point:** The 3-month rule: give copper IUCDs a 3-month trial with NSAID support before removal. Most women experience improvement in bleeding and pain by 3–6 months as the endometrium adapts. ## Pharmacological Options for Menorrhagia | Agent | Mechanism | Efficacy in IUCD Users | Dosing | |-------|-----------|------------------------|--------| | **Mefenamic acid** | Prostaglandin inhibitor + antagonist | 20–50% ↓ blood loss | 500 mg TDS during menses | | **Ibuprofen** | Prostaglandin inhibitor | 15–30% ↓ blood loss | 400–600 mg TDS during menses | | **Naproxen** | Prostaglandin inhibitor | 15–30% ↓ blood loss | 250–500 mg BD during menses | | **Tranexamic acid** | Antifibrinolytic | 30–50% ↓ blood loss | 1 g QID during menses | **Clinical Pearl:** Tranexamic acid (option D) is effective but is typically reserved for second-line use or combined with NSAIDs. Starting with NSAIDs alone is more cost-effective and addresses both bleeding and dysmenorrhea. ## Why Each Alternative is Suboptimal at This Stage **Immediate removal and LNG-IUS insertion (Option A):** - Premature. The patient is only 6 weeks post-insertion, still within the adaptation period. - Unnecessary IUCD exchange exposes the patient to reinsertion risks and costs. - Should be reserved for intolerable symptoms after 3 months of medical management. **Hysteroscopy (Option C):** - Not indicated. The IUCD is correctly positioned on imaging. - No clinical signs of perforation, expulsion, or infection. - Hysteroscopy is reserved for cases of suspected IUCD malposition, perforation, or persistent bleeding unresponsive to medical therapy after 3–6 months. **Tranexamic acid alone (Option D):** - Effective but not first-line. It addresses bleeding but not dysmenorrhea. - NSAIDs are preferred because they treat both symptoms and address the underlying mechanism (prostaglandin excess). - Tranexamic acid can be added if NSAIDs alone are insufficient after 4–6 weeks. ## Counseling Points **High-Yield:** Counsel the patient that: 1. Menorrhagia and dysmenorrhea are expected in the first 3–6 months with copper IUCDs. 2. Most women improve with NSAID support. 3. If symptoms persist after 3 months despite NSAIDs, removal and alternative contraception (e.g. LNG-IUS) are options. 4. The copper IUCD remains highly effective for contraception (Pearl Index 0.8) even with increased bleeding. **Tip:** Prescribe mefenamic acid to be taken during menses only (not continuously) to maximize efficacy and minimize side effects. Start 1–2 days before expected menses or at first sign of bleeding.